We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Aug 11, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation – one of the world’s largest pharmaceutical services companies. The company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcome. The company currently has a Zacks Rank #3 (Hold).
AmerisourceBergen had an unimpressive run on the bourse over the last one month, trading below the industry in terms of price performance. A glimpse at the share price movement reveals that AmerisourceBergen’s shares has lost 13.9%, comparing unfavorably with the 5.4% decline of the broader industry.
The unfavorable performance was led by pricing pressure in the generic drug space and lackluster guidance for the full year. AmerisourceBergen expects fiscal 2017 revenue growth in the range of 5.5% to 6.5%, significantly lower than the previous 6.5% to 8% band. The company expects brand drug inflation in the range of 7% to 9%.
AmerisourceBergen took over PharMEDium Healthcare Holdings for $2.58 billion back in 2015. We believe that the temporary slowdown in PharMEDium growth will mar AmerisourceBergen's bottom line in the coming quarters. Notably, the company aims to boost its investments to enhance PharMEDium's QA and QC (quality assurance and quality control) systems in terms of product quality and patient safety. Although this lends AmerisourceBergen a competitive advantage over the long haul, this might result in a bottom-line headwind for the business in fiscal 2017.
Lackluster performance in the hepatitis C revenue segment is another concern. In this regard, AmerisourceBergen witnessed a significant negative revenue impact from the declining sales at the segment in the second quarter. Revenues improved only 4% to $37.1 billion in the quarter, which might have been around 5.5% without the adverse impact of the hepatitis C segment.
Cutthroat competition in the niche space is an added concern. AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health care services market. The company’s primary competitors include Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) along with national generic and regional distributors.
The generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality along with regulatory challenges. The company also faces competition from manufacturers, chain drugstores, specialty distributors and packaging and health care technology companies.
Align Technology has an expected long-term adjusted earnings growth of almost 26.6%. The stock has added roughly 24.6% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
On Aug 11, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation – one of the world’s largest pharmaceutical services companies. The company focuses on providing drug distribution and related services to reduce health care costs and improve patient outcome. The company currently has a Zacks Rank #3 (Hold).
AmerisourceBergen had an unimpressive run on the bourse over the last one month, trading below the industry in terms of price performance. A glimpse at the share price movement reveals that AmerisourceBergen’s shares has lost 13.9%, comparing unfavorably with the 5.4% decline of the broader industry.
The unfavorable performance was led by pricing pressure in the generic drug space and lackluster guidance for the full year. AmerisourceBergen expects fiscal 2017 revenue growth in the range of 5.5% to 6.5%, significantly lower than the previous 6.5% to 8% band. The company expects brand drug inflation in the range of 7% to 9%.
AmerisourceBergen took over PharMEDium Healthcare Holdings for $2.58 billion back in 2015. We believe that the temporary slowdown in PharMEDium growth will mar AmerisourceBergen's bottom line in the coming quarters. Notably, the company aims to boost its investments to enhance PharMEDium's QA and QC (quality assurance and quality control) systems in terms of product quality and patient safety. Although this lends AmerisourceBergen a competitive advantage over the long haul, this might result in a bottom-line headwind for the business in fiscal 2017.
Lackluster performance in the hepatitis C revenue segment is another concern. In this regard, AmerisourceBergen witnessed a significant negative revenue impact from the declining sales at the segment in the second quarter. Revenues improved only 4% to $37.1 billion in the quarter, which might have been around 5.5% without the adverse impact of the hepatitis C segment.
Cutthroat competition in the niche space is an added concern. AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health care services market. The company’s primary competitors include Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) along with national generic and regional distributors.
The generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality along with regulatory challenges. The company also faces competition from manufacturers, chain drugstores, specialty distributors and packaging and health care technology companies.
A better-ranked stock in the broader medical sector is Align Technology, Inc. (ALGN - Free Report) , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 26.6%. The stock has added roughly 24.6% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>